Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;36(1):1-4.

Using Epigenetic Therapy to Overcome Chemotherapy Resistance

Julius Strauss  1 , William D Figg  2
Affiliations
Review

Using Epigenetic Therapy to Overcome Chemotherapy Resistance

Julius Strauss et al. Anticancer Res. 2016 Jan.

Abstract

It has been known for decades that as cancer progresses, tumors develop genetic alterations, making them highly prone to developing resistance to therapies. Classically, it has been thought that these acquired genetic changes are fixed. This has led to the paradigm of moving from one cancer therapy to the next while avoiding past therapies. However, emerging data on epigenetic changes during tumor progression and use of epigenetic therapies have shown that epigenetic modifications leading to chemotherapy resistance have the potential to be reversible with epigenetic therapy. In fact, promising clinical data exist that treatment with epigenetic agents can diminish chemotherapy resistance in a number of tumor types including chronic myelogenous leukemia, colorectal, ovarian, lung and breast cancer. The potential for epigenetic-modifying drugs to allow for treatment of resistant disease is exciting and clinical trials have just begun to evaluate this area.

Keywords: Epigenetic therapy; chemotherapy resistance; review.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jelinek J, Gharibyan V, Estecio MRH, Kondo K, Rong H, Woonbok C, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE and Issa JPJ: Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS ONE 6(7): e22110, 2011. - PMC - PubMed
    1. Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD and Kim SH: Bcr–Abl independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacal Exp Ther 322: 1084–1092, 2007. - PubMed
    1. Zhang YW, Zheng Y, Wang JZ, Lu XX, Wang Z, Chen LB, Guan XX and Tong JD: Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics 9(6): 896–909, 2014. - PMC - PubMed
    1. Ooki A, Yamashita K, Yamaguchi K, Mondai A, Nishimiya H and Watanabe M: DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Mol Cancer Res 11: 1362–1374, 2013. - PubMed
    1. Van Engeland M, Derks S, Smits KM, Meijer GA and Herman JG: Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29: 1382–1391, 2011. - PubMed

MeSH terms

Substances

LinkOut - more resources